VolitionRX Ltd (VNRX)

Over the past six months, VolitionRX Ltd. stock has experienced a notable decline, with a 52-week range between $0.22 and $0.94. As of February 6, 2026, the stock closed at $0.246, down from $0.2556 at the beginning of 2026, representing a decrease of 3.8%. VolitionRx issued a Business Review of 2025, highlighting progress in cancer and sepsis tests and outlining considerable multi-billion-dollar total addressable markets for its technologies. Freedom Capital Markets and H.C. Wainwright maintained a "Buy" rating with price targets of $2.00 and $2.50, respectively. Insider buying activity was reported. The company announced its Second Quarter 2025 financial results, reporting $0.4 million in revenue for Q2 and a 15% growth in H1 2025, with a reduced net loss. The stock price moved over -5.26% to $0.270 and later rose above its 50-day moving average to $0.29. The stock price fell by -0.405% to $0.246, marking its third consecutive day of decline and an overall drop of -12.77% over the preceding 10 days, with technical analysis indicating "sell signals".

Information directly detailing the demand seasonality for VolitionRX Ltd.'s specific products and services is not explicitly provided. Demand is likely driven more by disease prevalence, diagnostic needs, and healthcare trends rather than traditional seasonal consumer patterns. Factors such as the timing of clinical trial results, regulatory approvals, product launches, and partnerships would likely have a more significant impact on demand and revenue than seasonal variations. The veterinary cancer test, Nu.Q Vet, might see some minor seasonality related to routine pet check-ups, but this is speculative without direct data.

VolitionRX Limited is a multinational epigenetics company focused on improving outcomes for humans and animals with life-altering diseases through earlier detection and disease/treatment monitoring, operating in the Healthcare sector, specifically in the Medical Devices and In Vitro & in Vivo Diagnostic Substances industries. The company's core business revolves around its Nucleosomics® technology, which identifies and measures epigenetic and structural changes in nucleosomes in blood samples to detect disease-specific biomarkers, developing and commercializing blood tests to diagnose and monitor conditions, including cancers and diseases associated with NETosis. Its major product pillars include Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR and Capture-Seq technologies.

VolitionRX Limited is a multinational company with a significant global presence, developing blood tests for use in the United States, Europe, and Asia. The company's research and development activities are primarily centered in Belgium, with additional innovation laboratories and offices in the U.S., and further offices in London and Singapore. VolitionRX has also established distribution collaborations in Europe and Southeast Asia.

VolitionRX has maintained a focus on advancing its epigenetics science and expanding the utility of its Nu.Q® platform. The company has made continued progress in clinical and commercial aspects of its technology, with the Nu.Q® platform becoming a leading test in canine cancer and showing promise in NETs detection and monitoring. The company is actively pursuing commercialization in human diagnostics and sponsoring symposiums to raise awareness and credibility. Announcements of data supporting the use of Nu.Q® NETs in new indications and continued efforts to extend access to the Nu.Q® Vet Cancer Test have been made. A groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes has been introduced. The company acknowledged that the market has been "tough" and the stock price has seen a decline, which could impact investor sentiment, despite analysts generally rating VNRX as a "Buy". The company reported a net loss in 2024, although it was a reduction from the previous year.

VolitionRX Limited has a diverse ownership structure comprising institutional, retail, and individual investors. As of January 30, 2026, 33 institutional owners hold a total of 26,122,135 shares, with key institutional shareholders including Lagoda Investment Management, L.P., Armistice Capital, Llc, and Vanguard Group Inc. Approximately 1.57% of the company's stock is owned by Institutional Investors. Individual insiders own approximately 10.40% of the company's stock, totaling 9,137,264 shares, with notable individual owners and executives including Cameron Reynolds, Guy Innes, and Timothy Still, all with recent share purchases.